These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 10618605)
21. Which system is better to predict prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization as initial therapy? Comparison between CLIP and JIS in a Japanese population. Urakawa H; Kora SI; Mitsufuji T; Osame A; Higahsihara H; Yoshimitsu K Acta Radiol; 2016 Dec; 57(12):1445-1452. PubMed ID: 26861204 [TBL] [Abstract][Full Text] [Related]
22. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059 [TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054 [TBL] [Abstract][Full Text] [Related]
24. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Uraki J; Yamakado K; Nakatsuka A; Takeda K Eur J Radiol; 2004 Jul; 51(1):12-8. PubMed ID: 15186879 [TBL] [Abstract][Full Text] [Related]
25. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization]. Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805 [TBL] [Abstract][Full Text] [Related]
26. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547 [TBL] [Abstract][Full Text] [Related]
27. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L; Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076 [TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846 [TBL] [Abstract][Full Text] [Related]
29. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Zheng JS; Long J; Sun B; Lu NN; Fang D; Zhao LY; Du N Clin Radiol; 2014 Jun; 69(6):e253-63. PubMed ID: 24581962 [TBL] [Abstract][Full Text] [Related]
30. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y; Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600 [TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Kong JY; Li SM; Fan HY; Zhang L; Zhao HJ; Li SM Medicine (Baltimore); 2018 Aug; 97(33):e11872. PubMed ID: 30113483 [TBL] [Abstract][Full Text] [Related]
32. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692 [TBL] [Abstract][Full Text] [Related]
33. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients. Allgaier HP; Deibert P; Olschewski M; Spamer C; Blum U; Gerok W; Blum HE Int J Cancer; 1998 Dec; 79(6):601-5. PubMed ID: 9842968 [TBL] [Abstract][Full Text] [Related]
34. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Kim CJ; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Kim MJ Liver Int; 2014 Feb; 34(2):305-12. PubMed ID: 23890360 [TBL] [Abstract][Full Text] [Related]
35. [Prognostic significance of serum gamma-glutamyl transferase before transcatheter arterial chemoembolization in patients with hepatitis C virus-related hepatocellular carcinoma]. Chang ZF; Liu FY; Duan F; Wang ZJ; Yan JY; Wang MQ Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):202-5. PubMed ID: 26988826 [TBL] [Abstract][Full Text] [Related]
36. [Transcatheter arterial chemoembolization plus percutaneous thermal ablation in large hepatocellular carcinoma: clinical observation of efficacy and predictors of prognostic factors]. Fan WZ; Yang JY; Lü MD; Xie XY; Yin XY; Huang YH; Kuang M; Li HP; Xu HX; Li JP Zhonghua Yi Xue Za Zhi; 2011 Aug; 91(31):2190-4. PubMed ID: 22094036 [TBL] [Abstract][Full Text] [Related]
37. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861 [TBL] [Abstract][Full Text] [Related]
38. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. Jun CH; Ki HS; Lee HK; Park KJ; Park SY; Cho SB; Park CH; Joo YE; Kim HS; Choi SK; Rew JS World J Gastroenterol; 2013 Jan; 19(2):284-9. PubMed ID: 23345952 [TBL] [Abstract][Full Text] [Related]
39. The influence on liver function after transcatheter arterial chemoembolization combined with percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. Li JX; Wu H; Huang JW; Zeng Y J Formos Med Assoc; 2012 Sep; 111(9):510-5. PubMed ID: 23021508 [TBL] [Abstract][Full Text] [Related]
40. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]